151 related articles for article (PubMed ID: 22925831)
1. What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.
Westmark CJ
Mol Psychiatry; 2013 Apr; 18(4):425-34. PubMed ID: 22925831
[TBL] [Abstract][Full Text] [Related]
2. The functional neurophysiology of the amyloid precursor protein (APP) processing pathway.
Randall AD; Witton J; Booth C; Hynes-Allen A; Brown JT
Neuropharmacology; 2010; 59(4-5):243-67. PubMed ID: 20167227
[TBL] [Abstract][Full Text] [Related]
3. From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein.
Octave JN; Pierrot N; Ferao Santos S; Nalivaeva NN; Turner AJ
J Neurochem; 2013 Jul; 126(2):183-90. PubMed ID: 23495999
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
5. [Alzheimer's disease, amyloid peptide and synaptic dysfunction].
Hémar A; Mulle C
Med Sci (Paris); 2011; 27(8-9):733-6. PubMed ID: 21880261
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
8. Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.
Wang H; Megill A; He K; Kirkwood A; Lee HK
Neural Plast; 2012; 2012():272374. PubMed ID: 22792491
[TBL] [Abstract][Full Text] [Related]
9. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
10. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations.
Tampellini D; Rahman N; Gallo EF; Huang Z; Dumont M; Capetillo-Zarate E; Ma T; Zheng R; Lu B; Nanus DM; Lin MT; Gouras GK
J Neurosci; 2009 Aug; 29(31):9704-13. PubMed ID: 19657023
[TBL] [Abstract][Full Text] [Related]
11. Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis.
Marcello E; Epis R; Di Luca M
Eur J Pharmacol; 2008 May; 585(1):109-18. PubMed ID: 18377893
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
Boddapati S; Levites Y; Sierks MR
J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
15. Control of amyloid-beta-peptide generation by subcellular trafficking of the beta-amyloid precursor protein and beta-secretase.
Walter J
Neurodegener Dis; 2006; 3(4-5):247-54. PubMed ID: 17047364
[TBL] [Abstract][Full Text] [Related]
16. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
17. Synaptic retrogenesis and amyloid-beta in Alzheimer's disease.
Wasling P; Daborg J; Riebe I; Andersson M; Portelius E; Blennow K; Hanse E; Zetterberg H
J Alzheimers Dis; 2009; 16(1):1-14. PubMed ID: 19158416
[TBL] [Abstract][Full Text] [Related]
18. Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.
Westmark CJ; Sokol DK; Maloney B; Lahiri DK
Mol Psychiatry; 2016 Oct; 21(10):1333-41. PubMed ID: 27573877
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
